Li Li, commissioner of China's National Medical Products Administration (NMPA), signed a memorandum of understanding (MoU) on cooperation with Hisham S Aljadhey, chief executive officer of the Saudi Food and Drug Authority (SFDA), on Nov 1 in Beijing, to further enhance bilateral exchanges and cooperation in drug regulation.

Prior to the signing of the MoU, covering the regulation of drugs, medical instruments, and cosmetics, Li held talks with Aljadhey, during which he briefed Aljadhey on China's drug regulation work and the development of its pharmaceutical industry.

Li said that, in recent years, the NMPA has established a scientific, efficient and authoritative drug regulatory system, effectively maintaining the overall stability of drug safety and promoting the high-quality development of the pharmaceutical industry through strict, efficient and fair regulation.

Aljadhey introduced the development strategy of Saudi Arabia, the basic information of the SFDA, its laboratories and testing work.

The two sides agreed to actively implement the MoU and jointly promote more better pharmaceutical products to benefit the two peoples.

Officials from related NMPA organizations and affiliated institutions attended the meeting.